IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, Bitting RL, Kucuk O, Millard F, Seigne JD, Fling SP, Maecker HT, Duault C, Ramchurren N, Hess B, D'Amico L, Lacroix A, Kaiser JC, Morre M, Grégoire A, Cheever M, Yu EY, Fong L.
Pachynski RK, et al.
J Immunother Cancer. 2021 Aug;9(8):e002903. doi: 10.1136/jitc-2021-002903.
J Immunother Cancer. 2021.
PMID: 34452927
Free PMC article.
Clinical Trial.